Marc FARAGGI

Prof. Marc FARAGGI

Centre Hospitalier Princesse Grace
+1
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WEWilliam Echavidre
William Echavidre
VPVincent Picco
Vincent Picco
MFMarc FARAGGI
Marc FARAGGI
Christopher MontemagnoChristopher Montemagno
Christopher Montemagno
Glioblastoma (GBM), the most common primary malignant brain tumor, is associated with a dismal prognosis. Standard therapies including maximal surgical resection, radiotherapy, and temozolomide chemotherapy remain poorly efficient. Improving GBM treatment modalities is, therefore, a paramount challenge for researchers and clinicians. GBMs exhibit the hallmark feature of aggressive invasion into the surrounding tissue. Among cell surface receptors involved in this process, members of the integrin family are known to be key actors of GBM invasion. Upregulation of integrins was reported in both tumor and stromal cells, making them a suitable target for innovative therapies targeting integrins in GBM patients, as their impairment disrupts tumor cell proliferation and invasive capacities. Among them, integrin-αvβ3 expression correlates with high-grade GBM. Driven by a plethora of preclinical biological studies, antagonists of αvβ3 rapidly became attractive therapeutic candidates to impair GBM tumorigenesis. In this perspective, the advent of nuclear medicine is currently one of the greatest components of the theranostic concept in both preclinical and clinical research fields. In this review, we provided an overview of αvβ3 expression in GBM to emphasize the therapeutic agents developed. Advanced current and future developments in the theranostic field targeting αvβ3 are finally discussed.

25 July 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MDMatthieu Dietz
Matthieu Dietz
GCGilles Chironi
Gilles Chironi
YCYann-Erick Claessens
Yann-Erick Claessens
RFRyan Lukas Farhad
Ryan Lukas Farhad
IRIsabelle Rouquette
Isabelle Rouquette
DTD. Tran
D. Tran

2 June 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
OROlivier Riou
Olivier Riou
BSBenjamin Serrano
Benjamin Serrano
david azriadavid azria
david azria
BPBenoit Paulmier
Benoit Paulmier
RVRémy Villeneuve
Rémy Villeneuve
Juliette THARIATJuliette THARIAT
Juliette THARIAT
To assess the feasibility and benefit of integrating four-dimensional (4D) Positron Emission Tomography (PET) – computed tomography (CT) for liver stereotactic body radiation therapy (SBRT) planning. 8 patients with 14 metastases were accrued in the study. They all underwent a non-gated PET and a 4D PET centered on the liver. The same CT scan was used for attenuation correction, registration, and considered the planning CT for SBRT planning. Six PET phases were reconstructed for each 4D PET. By applying an individualized threshold to the 4D PET, a Biological Internal Target Volume (BITV) was generated for each lesion. A gated Planning Target Volume (PTVg) was created by adding 3 mm to account for set-up margins. This volume was compared to a manual Planning Target Volume (PTV) delineated with the help of a semi-automatic Biological Target Volume (BTV) obtained from the non-gated exam. A 5 mm radial and a 10 mm craniocaudal margins were applied to account for tumor motion and set-up margins to create the PTV. One undiagnosed liver metastasis was discovered thanks to the 4D PET. The semi-automatic BTV were significantly smaller than the BITV (p = 0.0031). However, after applying adapted margins, 4D PET allowed a statistically significant decrease in the PTVg as compared to the PTV (p = 0.0052). In comparison to non-gated PET, 4D PET may better define the respiratory movements of liver targets and improve SBRT planning for liver metastases. Furthermore, non respiratory-gated PET exams can both misdiagnose liver metastases and underestimate the real internal target volumes.

Verified
Journal Article
Open access
PDF file
Christopher MontemagnoChristopher Montemagno
Christopher Montemagno
Shamir CASSIMShamir CASSIM
Shamir CASSIM
NLNicolas de Leiris
Nicolas de Leiris
JDJerome Durivault
Jerome Durivault
MFMarc FARAGGI
Marc FARAGGI
Gilles PagèsGilles Pagès
Gilles Pagès
Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly devastating disease associated with poor prognosis. The lack of accurate diagnostic tests and failure of conventional therapies contribute to this pejorative issue. Over the last decade, the advent of theranostics in nuclear medicine has opened great opportunities for the diagnosis and treatment of several solid tumors. Several radiotracers dedicated to PDAC imaging or internal vectorized radiotherapy have been developed and some of them are currently under clinical consideration. The functional information provided by Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) could indeed provide an additive diagnostic value and thus help in the selection of patients for targeted therapies. Moreover, the therapeutic potential of β-- and α-emitter-radiolabeled agents could also overcome the resistance to conventional therapies. This review summarizes the current knowledge concerning the recent developments in the nuclear medicine field for the management of PDAC patients.

3 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
WEWilliam Echavidre
William Echavidre
DFDaniel Fagret
Daniel Fagret
MFMarc FARAGGI
Marc FARAGGI
VPVincent Picco
Vincent Picco
Christopher MontemagnoChristopher Montemagno
Christopher Montemagno
The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.

1 December 1995 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
FCF. Cavaillolès
F. Cavaillolès
JBJ. P. Bazin
J. P. Bazin
DPD. Pavel
D. Pavel
Elena OleaElena Olea
Elena Olea
MFMarc FARAGGI
Marc FARAGGI
RPR. Di Paola
R. Di Paola